Free Trial
OTCMKTS:AIMD

Ainos (AIMD) Stock Price, News & Analysis

Ainos logo
$0.55 -0.01 (-0.91%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.53 -0.01 (-2.39%)
As of 04/25/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ainos Stock (OTCMKTS:AIMD)

Key Stats

Today's Range
$0.54
$0.57
50-Day Range
$0.46
$0.66
52-Week Range
$0.40
$1.46
Volume
81,720 shs
Average Volume
564,485 shs
Market Capitalization
$8.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Receive AIMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ainos and its competitors with MarketBeat's FREE daily newsletter.

AIMD Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Ainos, ugo to develop robot with sense of smell
See More Headlines

AIMD Stock Analysis - Frequently Asked Questions

Ainos' stock was trading at $0.4560 at the beginning of 2025. Since then, AIMD shares have increased by 19.5% and is now trading at $0.5450.
View the best growth stocks for 2025 here
.

Shares of Ainos reverse split on the morning of Tuesday, August 9th 2022. The 1-15 reverse split was announced on Tuesday, August 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of AIMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ainos investors own include CRISPR Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Vistagen Therapeutics (VTGN), Alpha Lithium (APHLF), Baidu (BIDU), DiDi Global (DIDIY) and Kingsoft Cloud (KC).

Company Calendar

Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Medical Devices
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:AIMD
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,010,000.00
Net Margins
-515.80%
Pretax Margin
-515.76%

Debt

Sales & Book Value

Annual Sales
$20,729.00
Price / Cash Flow
N/A
Book Value
$1.50 per share
Price / Book
0.36

Miscellaneous

Free Float
13,322,000
Market Cap
$8.41 million
Optionable
Not Optionable
Beta
1.83
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:AIMD) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners